Identification
NameEG009
Accession NumberDB04907
TypeBiotech
GroupsInvestigational
Description

Cerepro is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
Synonyms
Sitimagene ceradenovec
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CereproNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
Pharmacology
Indication

Intended for the treatment of brain cancer.

Structured Indications Not Available
Pharmacodynamics

EG009 is comprised of a gene encased in a virus vector. Vectors transfer their gene payload into target cells, a process known as transfection, which use this new genetic material as a blueprint for the production of new beneficial proteins. EG009 uses a well-established adenoviral vector (Ad5) to introduce the gene that causes cells to express a protein called thymidine kinase (TK). Following the standard surgery to remove the solid tumour mass, EG009 is injected through the wall of the cavity left behind by the surgical removal of the solid tumour, into the surrounding healthy brain tissue. In the following days, the healthy cells in the wall of the cavity express TK. Five days after surgery, the drug ganciclovir (GCV) is given to the patient as part of the overall EG009 treatment regimen. Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide. Since cell division is a key characteristic of cancer and the normal brain cells are not dividing, cells that try to divide to form a new tumour around the site of the removal of the original tumour are targeted for destruction by the EG009 treatment. EG009 thus works by harnessing healthy cells to produce the substances necessary to destroy newly growing cancer cells.

Mechanism of action

EG009 works by delivering a gene into the healthy brain cells remaining after the tumour has been removed. These then produce an enzyme that kills the cells trying to divide, preventing a recurrence of a tumour.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of EG009.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of EG009.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with EG009.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of EG009.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of EG009.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of EG009.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of EG009.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of EG009.Experimental
OuabainOuabain may decrease the cardiotoxic activities of EG009.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with EG009.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of EG009.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesL01XX37 — Sitimagene ceradenovec
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24